The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Incyte
Stock and Other Ownership Interests - Incyte
Pembrolizumab (pembro) plus epacadostat or placebo for locally advanced or metastatic urothelial carcinoma (UC) after failure of first-line platinum-containing chemotherapy: KEYNOTE-698/ECHO-303.
 
Thomas Powles
Honoraria - Bristol-Myers Squibb; MERCK; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Merck; Novartis
Research Funding - AstraZeneca/MedImmune; Roche/Genentech
Other Relationship - Bristol-Myers Squibb; Ipsen
 
Joaquim Bellmunt
Honoraria - UpToDate
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech; Merck; Novartis; Pfizer; Pierre Fabre
Research Funding - Millennium (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - MSD Oncology; Pfizer
 
Daniel Peter Petrylak
Stock and Other Ownership Interests - Bellicum Pharmaceuticals; TYME
Consulting or Advisory Role - Bayer; Bellicum Pharmaceuticals; Dendreon; Exelixis; Ferring; Johnson & Johnson; Medivation; Millennium; Pfizer; Roche; Sanofi; TYME
Research Funding - Agensys; Astellas Medivation; AstraZeneca; Bayer; Dendreon; Endocyte; Genentech; Innocrin Pharma; Johnson & Johnson; Lilly; MedImmune; Merck; Millennium; Novartis; Oncogenex; Pfizer; Progenics; Roche; Sanofi; Seagen; Sotio
Expert Testimony - Celgene; sanofi
 
Lawrence Fong
Consulting or Advisory Role - Atreca; IDEAYA Biosciences; MIODx
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); Janssen Oncology (Inst); Merck (Inst); Roche/Genentech (Inst)
 
Hiroyuki Nishiyama
Honoraria - Astellas Pharma
Consulting or Advisory Role - Bayer Yakuhin; Chugai Pharma; Janssen; Lilly; MSD
Speakers' Bureau - Bristol-Myers Squibb
Research Funding - Astellas Pharma (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Takeda (Inst)
 
Cora N. Sternberg
No Relationships to Disclose
 
Mei Chen
Employment - Merck
Stock and Other Ownership Interests - GlaxoSmithKline; Merck
 
Lei Pang
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck Sharp & Dohme
 
Mihaela Munteanu
No Relationships to Disclose
 
Yufan Zhao
Employment - Amgen
Stock and Other Ownership Interests - Amgen
Travel, Accommodations, Expenses - Amgen
 
David C. Smith
Consulting or Advisory Role - Merck
Research Funding - Agensys (Inst); Astellas Pharma (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb/Medarex (Inst); ESSA (Inst); Exelixis (Inst); Genentech (Inst); Incyte (Inst); Lilly (Inst); MedImmune (Inst); Medivation/Astellas (Inst); Merck (Inst); Millendo (Inst); Novartis (Inst); OncoMed (Inst); Seagen (Inst)